Interim results from a small group of children in a Phase I/II trial are essentially in line with that of Elevidys, according ...

You can reach Jason on Signal at JasonMast.05. Sarepta Therapeutics said Tuesday that a 16-year-old boy died after receiving Elevidys, its gene therapy for Duchenne muscular dystrophy, the first ...

Sarepta Therapeutics stock dropped over 20% after a patient treated with Elevidys for DMD died from acute liver failure, raising safety concerns. Despite the incident, Sarepta maintains that the ...

The Platform Technology Designation, which predates the current FDA leadership, is designed to streamline the drug ...

We recently published a list of 10 Stocks Investors Dumped Fast. In this article, we are going to take a look at where ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogene ...

One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech said (PDF) Tuesday. The patient suffered ...

Sarepta and Roche paused multiple Elevidys trials in the EU at the EMA’s request. HC Wainwright upgraded Sarepta to Neutral but sees Elevidys sales falling by Q2 2025. Ready to turn the market ...

WASHINGTON (dpa-AFX) - Sarepta Therapeutics, Inc. (SRPT), Tuesday said that the Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Elevidys for the treatment of Duchenne muscular ...

Sarepta Therapeutics said Tuesday that a 16-year-old boy died after receiving Elevidys, its gene therapy for Duchenne muscular dystrophy, the first known death linked to the treatment. The ...